Morbidly Obesity Roux-en-y Gastric bypass, Lansoprazole, Pharmacokinetics
Conditions
Interventions
30mg twice daily starting at 2 weeks before surgery and continue the drug for 6 weeks after surgery
Experimental Drug
Lansoprazole
Sponsors
Ratchadapisek Sompoch Endowment Fund Chulalongkorn university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The target population is obese patients admitted to Chulalongkorn Hospital which have indications for surgery according to National Institute of Health (NIH) guidelines that are BMI> 40 kg / m2 or BMI> 35 kg / m2 and also have associated diseases such as diabetes, hypertension, coronary heart disease, sleep apnea, age over 18 years old and associated with peptic ulcers.
Exclusion criteria
Exclusion criteria: Patients with exclusion criteria are patients who had previously undergone bariatric surgery, unable to swallow drugs, taking statins for the dyslipidemia treatment, and in patients who is allergic to lansoprazole and or taking drug interacted with lansoprazole: Acalabrutinib, Atazanavir, Cilostazol, Citalopram, Dacomitinib, Dasatinib, Erlotinib, Methotrexate, Nelfinavir, Neratinib, Pazopanib, Pexidartinib, Rilpivirine, Tacrolimus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic of Lansoprazole 1 day before and 6 weeks after the surgery AUC of concentration of Lansoprazole in plasma, half-life, Cmax, Tmax | — |
Secondary
| Measure | Time frame |
|---|---|
| The difference of CYP polymorphism 1 day before surgery Type of CYP | — |
Countries
Thailand
Contacts
Public ContactSuthep Udomsawaengsup
Chulalongkorn hospital
Outcome results
None listed